Drug Discovery

Smarter investments to advance your drug discovery pipeline

The commercialization of new drugs is a long, complicated road that requires significant financial, people, and time investments. Making judicious decisions every step of the way is necessary to guarantee a successful and cost effective outcome, but making the right decision can be challenging with so many technology choices. An integrated partnership with Life Technologies can guide you in the right economic direction.View an example case study.

Make the most out of your drug discovery resources. Start a conversation with us at strategicalliances@lifetech.com.

Building integrated client solutions

Life Technologies offers the opportunity to access our ever-growing suite of technologies and scientific expertise to shape and support integrated drug discovery client programs. This breadth of domain IP and knowledge is utilized to create programs addressing different phases of drug discovery including target validation, assay development, lead identification and optimization, adme/toxicology and biomarker discovery. Tailored partnerships are built on a foundation of communication and understanding. Project goals are our first consideration and we have developed a dedicated infrastructure to design and manage these to a successful outcome.

• Strategic alliance management team―consults with client to recommend project framework and select optimal mix of our capabilities
• Dedicated project manager for your project―acts as the single point of contact once the project is established
• PhD scientist–led execution team―co-designs the scientific work plan with client and manages the functional execution

Oncology case study

One recent client partnership provides an example of how our portfolio of products and services can be leveraged to accelerate an oncology drug discovery program.

• Target generation—internal client challenges with target expression and purification were overcome using our portfolio of gene expression technologies and expertise in insect cell expression. Evaluation protein was delivered to client (5 weeks).
• HTS assay development—to support HTS and hit confirmation, our scientists developed a LanthaScreen® TR-FRET assay that met client performance criteria and delivered bulk HTS reagents (5 weeks).
• Secondary cellular assays—in parallel with the HTS campaign, we built a suite of cellular assays for lead optimization and SAR (WT target, disease variant, closest neighbor, and safety ortholog). Stable cell lines validated with reference compounds were delivered to the client (10 weeks).
• Secondary screening support—following identification of promising scaffolds, the client engaged with us to perform weekly medicinal chemistry screening support using the suite of developed cellular assays.
• Client impact:
  • Client technical hurdles resolved through partnership
  • Tailored screening reagents delivered in less than 5 months
  • Unique scaffolds identified from primary screen
  • Medicinal chemistry activated
  • Estimated client cost avoidance (FTE) = $1M

Discover the power of our drug discovery resources

Explore our capabilities or start a conversation with us now at strategicalliances@lifetech.com.